Private equity’s growing presence in American healthcare has long walked a tightrope between efficiency and intrusion. What once made the sector an appealing target – stable revenue streams, fragmented markets, and regulatory nuance – is now drawing increasing scrutiny.
But while federal policymakers once led the charge, today’s spotlight has shifted.
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day